GlassScriptPhysician profile
Kyla M D'Angelo
NPI 1669899829
$5,128.42
in general payments reported to CMS, 2019-2025
29 companies · $1,492 in 2025
The $1,492 reported for 2025 was more than what 78% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $600 · 2022: $404 · 2023: $745 · 2024: $1,887 · 2025: $1,492.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,059 · Education: $41.17 · Consulting Fee: $24.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,058.60 |
| Education | $41.17 |
| Consulting Fee | $24.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $654.28 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Abbott Laboratories | $470.49 | 2021-2024 | Jot Dx |
| Janssen Pharmaceuticals, INC | $458.49 | 2021-2024 | Xarelto |
| Boston Scientific Corporation | $416.81 | 2022-2024 | Watchman Flx, Watchman Access System |
| Boehringer Ingelheim Pharmaceuticals, INC. | $320.04 | 2021-2025 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $285.33 | 2023-2025 | Camzyos, Eliquis |
| Amgen INC. | $273.04 | 2023-2025 | Repatha, Repatha |
| Pfizer INC. | $265.16 | 2021-2025 | |
| Alnylam Pharmaceuticals INC. | $213.20 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $197.04 | 2025 | |
| Scpharmaceuticals INC. | $175.85 | 2023-2025 | |
| Bridgebio Pharma, INC. | $175.15 | 2025 | Attruby |
| Astrazeneca Pharmaceuticals LP | $164.22 | 2021-2025 | Farxiga, Wainua |
| Lexicon Pharmaceuticals, INC. | $155.93 | 2023-2024 | Inpefa |
| Bracco Diagnostics INC. | $143.60 | 2025 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $129.06 | 2024-2025 | |
| Biotronik INC. | $112.24 | 2022 | |
| Heartflow, INC. | $101.02 | 2025 | |
| Kiniksa Pharmaceuticals International, Plc | $74.37 | 2024 | Arcalyst |
| Merck Sharp & Dohme LLC | $71.02 | 2024 | Verquvo |
| Actelion Pharmaceuticals US, INC. | $59.98 | 2024-2025 | Uptravi, Opsumit, Opsynvi |
| Tactile Systems Technology INC | $50.64 | 2024-2025 | Flexitouch Plus, Nimbl, Entre Plus |
| Philips North America LLC | $29.37 | 2022 | |
| Baxter Healthcare | $24.99 | 2023 | Hillrom - Carnation Ambulatory Monitor |
| Angiodynamics, INC. | $24.86 | 2024 | Auryon Laser System 100-120 Vac |
| Esperion Therapeutics, INC. | $22.71 | 2024 | Nexletol |
| Glaxosmithkline, LLC. | $20.57 | 2025 | Shingrix |
| Daiichi Sankyo INC. | $19.73 | 2024 | Injectafer |
| Lilly USA, LLC | $19.23 | 2025 | Zepbound, Mounjaro |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kyla D'Angelo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.